|
Men % (n)
|
70.6 (89)
|
|
Age* (years)
|
45.9 ± 11.5
|
|
Symptom duration* (years)
|
8.1 ± 7.4
|
|
Disease duration* (years)
|
14.7 ± 10.0
|
|
Current medication % (n)
| |
|
None
|
12.7 (16)
|
|
NSAIDs
|
61.9 (78)
|
|
Biologicals
|
4.0 (5)
|
|
Combination
|
10.3 (13)
|
|
Other#
|
4.0 (5)
|
|
HLA-B27+ % (n)
|
77.8 (98)
|
|
ESR* (mm/hour)
|
10.4 ± 18.4
|
|
Extra-spinal symptoms % (n)
| |
|
psoriasis
|
4.8 (6)
|
|
uveitis
|
19.8 (25)
|
|
inflammatory bowel disease
|
4.0 (5)
|
|
arthritis
|
38.1 (48)
|
|
BASFI* (score 0-10)
|
4.9 ± 2.3
|
|
BASDAI* (score 0-10)
|
5.2 ± 2.3
|
|
BASMI* (score 0-10)
|
4.1 ± 2.0
|
- * mean ± standard deviation
- # e.g. sulfasalazine, methotrexate.
- BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; ESR, { Erythrocyte Sedimentation Rate NSAIDs, non-steroidal antiinflammatory drugs.
